Computer-aided discovery of biological activity spectra for anti-aging and anti-cancer olive oil oleuropeins

Aging

Volumn 6, Issue 9, 2014, Pages 731-741

  Corominas Faja, Bruna ^a,b   Santangelo, Elvira ^c   Cuyàs, Elisabet ^a,b   Micol, Vicente ^d   Joven, Jorge ^e   Ariza, Xavier ^c   Segura Carretero, Antonio ^f,g   García, Jordi ^c   Menendez, Javier A ^a,b  

^a CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^b GIRONA BIOMEDICAL RESEARCH INSTITUTE IDIBGI   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

^d MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

^e HOSPITAL UNIVERSITARI SANT JOAN DE REUS   (Spain)

^f UNIVERSITY OF GRANADA   (Spain)

^g Research and Development of Functional Food Centre (CIDAF)   (Spain)

Author keywords

Aging; Biological activity spectra; Cancer; Decarboxymethyl oleuropein aglycone; Oleuropein aglycone; PASS

Indexed keywords

ANTINEOPLASTIC AGENT; IRIDOID; OLEUROPEIN; OLIVE OIL; PLANT EXTRACT; POLYPHENOL; VEGETABLE OIL;

AGING; CHEMISTRY; DRUG DEVELOPMENT; DRUG EFFECTS; ISOLATION AND PURIFICATION; PROCEDURES;

AGING; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DRUG DISCOVERY; IRIDOIDS; PLANT EXTRACTS; PLANT OILS; POLYPHENOLS;

EID: 84907849093     PISSN: 19454589     EISSN: None     Source Type: Journal    
DOI: 10.18632/aging.100691     Document Type: Article

References (72)

1. Lamming DW, Wood JG and Sinclair DA. Small molecules that regulate lifespan: evidence for xenohormesis. Mol Microbiol. 2004; 53:1003-1009.
2. Howitz KT and Sinclair DA. Xenohormesis: sensing the chemical cues of other species. Cell. 2008; 133:387-391.
3. Hooper PL, Hooper PL, Tytell M and Vígh L. Xenohormesis: health benefits from an eon of plant stress response evolution. Cell Stress Chaperones. 2010; 15:761-770.
4. Surh YJ. Xenohormesis mechanisms underlying chemopreventive effects of some dietary phytochemicals. Ann N Y Acad Sci. 2011; 1229:1-6.
5. Testa G, Biasi F, Poli G and Chiarpotto E. Calorie Restriction and Dietary Restriction Mimetics: a Strategy for Improving Healthy Aging and Longevity. Curr Pharm Des. 2014; 20:2950-2977.
6. Chung JH, Manganiello V and Dyck JR. Resveratrol as a calorie restriction mimetic: therapeutic implications. Trends Cell Biol. 2012; 22:546-554.
7. Marchal J, Pifferi F and Aujard F. Resveratrol in mammals: effects on aging biomarkers, age-related diseases, and life span. Ann N Y Acad Sci. 2013; 1290:67-73.
8. Timmers S, Auwerx J and Schrauwen P. The journey of resveratrol from yeast to human. Aging (Albany NY). 2012;4:146-158.
9. Martins I, Galluzzi L and Kroemer G. Hormesis, cell death and aging. Aging (Albany NY). 2011; 3:821-828.
10. Fernández AF and Fraga MF. The effects of the dietary polyphenol resveratrol on human healthy aging and lifespan. Epigenetics. 2011; 6:870-874.
11. Agarwal B and Baur JA. Resveratrol and life extension. Ann N Y Acad Sci. 2011; 1215:138-143.
12. Mouchiroud L, Molin L, Dallière N and Solari F. Life span extension by resveratrol, rapamycin, and metformin: The promise of dietary restriction mimetics for an healthy aging. Biofactors. 2010; 36:377-382.
13. Blagosklonny MV. Hormesis does not make sense except in the light of TOR-driven aging. Aging (Albany NY). 2011; 3:1051-62.
14. Blagosklonny MV. Prevention of cancer by inhibiting aging. Cancer Biol Ther. 2008; 7:1520-1524.
15. Blagosklonny MV. Aging-suppressants: cellular senescence (hyperactivation) and its pharmacologic deceleration. Cell Cycle. 2009; 8:1883-1887.
16. Blagosklonny MV. TOR-driven aging: speeding car without brakes. Cell Cycle. 2009; 8:4055-4059.
17. Blagosklonny MV. Calorie restriction: decelerating mTORdriven aging from cells to organisms (including humans). Cell Cycle. 2010; 9:683-688.
18. Blagosklonny MV. Increasing healthy lifespan by suppressing aging in our lifetime: preliminary proposal. Cell Cycle. 2010;9:4788-4794.
19. Blagosklonny MV. Molecular damage in cancer: an argument for mTOR-driven aging. Aging (Albany NY). 2011; 3:1130-1141.
20. Blagosklonny MV. Rapalogs in cancer prevention: anti-aging or anticancer? Cancer Biol Ther. 2012; 13:1349-1354.
21. Blagosklonny MV. Cell cycle arrest is not yet senescence, which is not just cell cycle arrest: terminology for TOR-driven aging. Aging (Albany NY). 2012; 4:159-165.
22. Blagosklonny MV. Prospective treatment of age-related diseases by slowing down aging. Am J Pathol. 2012; 181:1142-1146.
23. Leontieva OV, Paszkiewicz GM and Blagosklonny MV. Mechanistic or mammalian target of rapamycin (mTOR) may determine robustness in young male mice at the cost of accelerated aging. Aging (Albany NY). 2012; 4:899-916.
24. Blagosklonny MV. Answering the ultimate question "what is the proximal cause of aging?". Aging (Albany NY). 2012; 4:861-877.
25. Blagosklonny MV. Common drugs and treatments for cancer and age-related diseases: revitalizing answers to NCI's provocative questions. Oncotarget. 2012; 3:1711-1724.
26. Blagosklonny MV. MTOR-driven quasi-programmed aging as a disposable soma theory: blind watchmaker vs. intelligent designer. Cell Cycle. 2013; 12:1842-1847.
27. Blagosklonny MV. Rapamycin extends life- and health span because it slows aging. Aging (Albany NY). 2013; 5:592-598.
28. Blagosklonny MV. Aging is not programmed: Genetic pseudo-program is a shadow of developmental growth. Cell Cycle. 2013; 12:3736-3742.
29. Menendez JA, Joven J, Aragonès G, Barrajón-Catalán E, Beltrán-Debón R, Borrás-Linares I, Camps J, Corominas-Faja B, Cufí S, Fernández-Arroyo S, Garcia-Heredia A, Hernández-Aguilera A, Herranz-López M, Jiménez-Sánchez C, López-Bonet E, Lozano-Sánchez J, et al. Xenohormetic and anti-aging activity of secoiridoid polyphenols present in extra virgin olive oil: a new family of gerosuppressant agents. Cell Cycle. 2013; 12:555-578.
30. Mariño G, Ugalde AP, Salvador-Montoliu N, Varela I, Quirós PM, Cadiñanos J, van der Pluijm I, Freije JM and López-Otín C. Premature aging in mice activates a systemic metabolic response involving autophagy induction. Hum Mol Genet. 2008;17:2196-2211.
31. Mariño G and López-Otín C. Autophagy and aging: new lessons from progeroid mice. Autophagy. 2008; 4:807-809.
32. Vazquez-Martin A, Fernández-Arroyo S, Cufí S, Oliveras-Ferraros C, Lozano-Sánchez J, Vellón L, Micol V, Joven J, Segura-Carretero A and Menendez JA. Phenolic secoiridoids in extra virgin olive oil impede fibrogenic and oncogenic epithelial-tomesenchymal transition: extra virgin olive oil as a source of novel antiaging phytochemicals. Rejuvenation Res. 2012;15:3-21.
33. Filimonov DA, Poroikov VV, Karaicheva EI, Kazarian RK, Budunova AP, Mikhailovskii EM, Rudnitskikh AV, Goncharenko LV and Burov IuV. [The computerized prediction of the spectrum of biological activity of chemical compounds by their structural formula: the PASS system. Prediction of Activity Spectra for Substance]. Eksp Klin Farmakol. 1995; 58:56-62.
34. Lagunin A, Stepanchikova A, Filimonov D and Poroikov V. PASS: prediction of activity spectra for biologically active substances. Bioinformatics. 2000; 16:747-748.
35. Poroikov VV, Filimonov DA, Ihlenfeldt WD, Gloriozova TA, Lagunin AA, Borodina YV, Stepanchikova AV and Nicklaus MC. PASS biological activity spectrum predictions in the enhanced open NCI database browser. J Chem Inf Comput Sci. 2003;43:228-236.
36. Stepanchikova AV, Lagunin AA, Filimonov DA and Poroikov VV. Prediction of biological activity spectra for substances: evaluation on the diverse sets of drug-like structures. Curr Med Chem. 2003; 10:225-233.
37. Filimonov DA and Poroikov VV. In: Chemoinformatics Approaches to Virtual Screening. Eds. Alexandre Varnek and Alexander Tropsha. Cambridge (UK): RSC Publishing. 2008. P.182-216.
38. Geronikaki AA, Lagunin AA, Hadjipavlou-Litina DI, Eleftheriou PT, Filimonov DA, Poroikov VV, Alam I and Saxena AK. Computeraided discovery of anti-inflammatory thiazolidinones with dual cyclooxygenase/lipoxygenase inhibition. J Med Chem. 2008;51:1601-1609.
39. Benaamane N, Nedjar-Kolli B, Bentarzi Y, Hammal L, Geronikaki A, Eleftheriou P and Lagunin A. Synthesis and in silico biological activity evaluation of new N-substituted pyrazolooxazin-2-one systems. Bioorg Med Chem. 2008; 16:3059-3066.
40. Lagunin A, Filimonov D and Poroikov V. Multi-targeted natural products evaluation based on biological activity prediction with PASS. Curr Pharm Des. 2010; 16:1703-1717.
41. Singh D, Gawande DY, Singh T, Poroikov V and Goel RK. Revealing pharmacodynamics of medicinal plants using in silico approach: a case study with wet lab validation. Comput Biol Med. 2014; 47:1-6.
42. Ivanov SM, Lagunin AA, Zakharov AV, Filimonov DA and Poroikov VV. [Computer search for molecular mechanisms of ulcerogenic action of nonsteroidal antiinflammatory drugs]. Biomed Khim. 2014; 60:7-16.
43. Kumar A, Lohan P, Aneja DK, Gupta GK, Kaushik D and Prakash O. Design, synthesis, computational and biological evaluation of some new hydrazino derivatives of DHA and pyranopyrazoles. Eur J Med Chem. 2012; 50:81-89.
44. Wu JY, Lin CY, Lin TW, Ken CF and Wen YD. Curcumin affects development of zebrafish embryo. Biol Pharm Bull. 2007;30:1336-1339.
45. Huang FJ, Lan KC, Kang HY, Liu YC, Hsuuw YD, Chan WH and Huang KE. Effect of curcumin on in vitro early post-implantation stages of mouse embryo development. Eur J Obstet Gynecol Reprod Biol. 2013; 166:47-51.
46. Hossain DM, Bhattacharyya S, Das T and Sa G. Curcumin: the multi-targeted therapy for cancer regression. Front Biosci (Schol Ed). 2012; 4:335-355.
47. Khan HY, Zubair H, Ullah MF, Ahmad A and Hadi SM. A prooxidant mechanism for the anticancer and chemopreventive properties of plant polyphenols. Curr Drug Targets. 2012;13:1738-1749.
48. Szekeres T, Saiko P, Fritzer-Szekeres M, Djavan B and Jäger W. Chemopreventive effects of resveratrol and resveratrol derivatives. Ann N Y Acad Sci. 2011; 1215:89-95.
49. Shukla Y and Singh R. Resveratrol and cellular mechanisms of cancer prevention. Ann N Y Acad Sci. 2011; 1215:1-8.
50. Park W, Amin AR, Chen ZG and Shin DM. New perspectives of curcumin in cancer prevention. Cancer Prev Res (Phila). 2013;6:387-400.
51. Puel C, Quintin A, Agalias A, Mathey J, Obled C, Mazur A, Davicco MJ, Lebecque P, Skaltsounis AL and Coxam V. Olive oil and its main phenolic micronutrient (oleuropein) prevent inflammation-induced bone loss in the ovariectomised rat. Br J Nutr. 2004; 92:119-127.
52. Giamarellos-Bourboulis EJ, Geladopoulos T, Chrisofos M, Koutoukas P, Vassiliadis J, Alexandrou I, Tsaganos T, Sabracos L, Karagianni V, Pelekanou E, Tzepi I, Kranidioti H, Koussoulas V and Giamarellou H. Oleuropein: a novel immunomodulator conferring prolonged survival in experimental sepsis by Pseudomonas aeruginosa. Shock. 2006; 26:410-416.
53. Poudyal H, Campbell F and Brown L. Olive leaf extract attenuates cardiac, hepatic, and metabolic changes in high carbohydrate-, high fat-fed rats. J Nutr. 2010; 140:946-953.
54. Kim Y, Choi Y and Park T. Hepatoprotective effect of oleuropein in mice: mechanisms uncovered by gene expression profiling. Biotechnol J. 2010; 5:950-960.
55. Impellizzeri D, Esposito E, Mazzon E, Paterniti I, Di Paola R, Bramanti P, Morittu VM, Procopio A, Britti D and Cuzzocrea S. The effects of oleuropein aglycone, an olive oil compound, in a mouse model of carrageenan-induced pleurisy. Clin Nutr. 2011;30:533-540.
56. Scoditti E, Calabriso N, Massaro M, Pellegrino M, Storelli C, Martines G, De Caterina R and Carluccio MA. Mediterranean diet polyphenols reduce inflammatory angiogenesis through MMP-9 and COX-2 inhibition in human vascular endothelial cells: a potentially protective mechanism in atherosclerotic vascular disease and cancer. Arch Biochem Biophys. 2012; 527:81-89.
57. Domitrovic R, Jakovac H, Marchesi VV, Šain I, Romic Ž and Rahelic D. Preventive and therapeutic effects of oleuropein against carbon tetrachloride-induced liver damage in mice. Pharmacol Res. 2012;65:451-64.
58. Impellizzeri D, Esposito E, Mazzon E, Paterniti I, Di Paola R, Morittu VM, Procopio A, Britti D and Cuzzocrea S. Oleuropein aglycone, an olive oil compound, ameliorates development of arthritis caused by injection of collagen type II in mice. J Pharmacol Exp Ther. 2011; 339:859-869.
59. Visioli F and Galli C. Antiatherogenic components of olive oil. Curr Atheroscler Rep. 2001;3:64-7.
60. Manna C, Migliardi V, Golino P, Scognamiglio A, Galletti P, Chiariello M and Zappia V. Oleuropein prevents oxidative myocardial injury induced by ischemia and reperfusion. J Nutr Biochem. 2004; 15:461-466.
61. Turner R, Etienne N, Alonso MG, de Pascual-Teresa S, Minihane AM, Weinberg PD and Rimbach G. Antioxidant and anti-atherogenic activities of olive oil phenolics. Int J Vitam Nutr Res. 2005; 75:61-70.
62. Omar SH. Cardioprotective and neuroprotective roles of oleuropein in olive. Saudi Pharm J. 2010; 18:111-121.
63. Rigacci S, Guidotti V, Bucciantini M, Nichino D, Relini A, Berti A and Stefani M. Aß(1-42) aggregates into non-toxic amyloid assemblies in the presence of the natural polyphenol oleuropein aglycon. Curr Alzheimer Res. 2011; 8:841-852.
64. Diomede L, Rigacci S, Romeo M, Stefani M and Salmona M. Oleuropein aglycone protects transgenic C. elegans strains expressing Aß42 by reducing plaque load and motor deficit. PLoS One. 2013; 8:e58893.
65. Grossi C, Rigacci S, Ambrosini S, Dami TE, Luccarini I, Traini C, Failli P, Berti A, Casamenti F and Stefani M. The polyphenol oleuropein aglycone protects TgCRND8 mice against Aß plaque pathology. PLoS One. 2013; 8:e71702.
66. Luccarini I, Ed Dami T, Grossi C, Rigacci S, Stefani M and Casamenti F. Oleuropein aglycone counteracts Aß42 toxicity in the rat brain. Neurosci Lett. 2014; 558:67-72.
67. Karkoula E, Skantzari A, Melliou E and Magiatis P. Direct measurement of oleocanthal and oleacein levels in olive oil by quantitative (1)H NMR. Establishment of a new index for the characterization of extra virgin olive oils. J Agric Food Chem. 2012; 60:11696-11703.
68. Vougogiannopoulou K, Lemus C, Halabalaki M, Pergola C, Werz O, Smith AB 3rd, Michel S, Skaltsounis L and Deguin B. One-step semisynthesis of oleacein and the determination as a 5-lipoxygenase inhibitor. J Nat Prod. 2014; 77:441-445.
69. Karkoula E, Skantzari A, Melliou E and Magiatis P. Quantitative Measurement of Major Secoiridoid Derivatives in Olive Oil Using qNMR. Proof of the Artificial Formation of Aldehydic Oleuropein and Ligstroside Aglycon Isomers. J Agric Food Chem. 2014 Jan 13. [Epub ahead of print]
70. Surh YJ. Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer. 2003; 3:768-780.
71. Scott EN, Gescher AJ, Steward WP and Brown K. Development of dietary phytochemical chemopreventive agents: biomarkers and choice of dose for early clinical trials. Cancer Prev Res (Phila). 2009; 2:525-530.
72. Wagh V, Jagtap S, Meganathan K, Potta SP, Winkler J, Hescheler J and Sachinidis A. Effect of chemopreventive agents on differentiation of mouse embryonic stem cells. Front Biosci (Elite Ed). 2012;4:156-168.